Affiliation:
1. Department of OB/GYN, Sutter Medical Center, Sacramento, CA, USA
Abstract
Introduction: High-grade endometrial stromal sarcoma (HG-ESS) is a rare and aggressive malignant neoplasm that has a poor prognosis and accounts for 0.2% of uterine malignancies. There is a lack of available information on HG-ESS due to its high case fatality rate. Due to the poor prognosis associated with HG-ESS, it is important to diagnose HG-ESS in its early stages.
Case Report: In this case report, we describe the case of a 63-year-old postmenopausal woman who presented with a pelvic mass and postmenopausal bleeding. The patient’s past history included a fibroid for which the patient underwent a successful uterine fibroid embolization. The patient underwent a pelvic ultrasound and an endometrial biopsy prior to gynecological consult. Both were inconclusive and led to an initial diagnosis of a uterine fibroid. After a gynecological consult and an additional biopsy, pathological examination revealed high-grade neoplastic cells that expressed strong and diffuse nuclear BCL1/Cyclin D1. The pattern of diffuse cyclin D1 expression and negative CD10 was suggestive of the YWHAE-rearranged subtype of HG-ESS. The combined morphologic and immunophenotypic features were consistent with a high-grade endometrial stromal sarcoma with fluorescence in situ hybridization (FISH) positivity for YWHAE gene rearrangement and FISH negativity for BCOR gene rearrangement. The patient underwent a robotic-assisted modified radical hysterectomy, radical pelvic tumor resection, bilateral salpingo-oophorectomy, sentinel pelvic lymph node dissections, and an appendectomy. The resulting surgical pathologic diagnosis was HG-ESS stage 1. Currently, no adjuvant therapy is recommended given negative margins with stage 1 status.
Conclusion: High-grade endometrial stromal sarcoma is a rare clinical entity in postmenopausal women which is initially misdiagnosed but should be included in the differential diagnosis of necrotic masses.
Publisher
Edorium Journals Pvt. Ltd.
Reference18 articles.
1. Wang F, Lei R, Yang H, Guo M, Tan G. Endometrial stromal sarcoma: A clinicopathological analysis of 14 cases. Int J Clin Exp Pathol 2018;11(5):2799–804.
2. Ali RH, Rouzbahman M. Endometrial stromal tumours revisited: An update based on the 2014 WHO classification. J Clin Pathol 2015;68(5):325–32.
3. Shekhar S, Sharma C, Elhence P, Bansal S, Garg N. A case of high-grade endometrial stromal sarcoma: A poignant allegory. J Midlife Health 2019;10(4):209–12.
4. Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK. Treatment options in stage I endometrial stromal sarcoma: A retrospective analysis of 53 cases. Gynecol Oncol 2008;108(2):306–11.
5. Smith PP, O’Connor S, Gupta J, Clark TJ. Recurrent postmenopausal bleeding: A prospective cohort study. J Minim Invasive Gynecol 2014;21(5):799–803.